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Through endocrinological studies, the role of metastin/GPR54 signaling in non-cancer tissue is at least partially understood. Continuous metastin stimulation desensitizes GPR54 signaling, resulting in the loss of downstream GnRH release in neurons (8) . The expression of GPR54 in female rat pituitary glands is positively regulated by GnRH and negatively controlled by chronic exposure to estradiol (9) . The G-protein coupled receptor serine/threonine kinase-2 (GRK2) mediates GPR54 desensitization in HEK293 cells, probably by interacting with the intracellular loop or cytoplasmic tail of GPR54 (10) . However, little is known about the regulation of GPR54 expression in cancer cells in spite of the demonstrated clinical impact and important roles in cancer biology that have been revealed. In this study, we demonstrate the clinical significance and epigenetic regulation of GPR54 expression in endometrial cancer and describe a potential role for the metastin peptide as a metastasis suppressor for clinical use. cycles of 95°C for 5sec and 60°C for 31sec, followed by a dissociation cycle of 95°C for 15sec, 60°C for 20sec, and 95°C for 15sec. The expression of human GPR54 mRNAs was estimated by dividing the
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GPR54 threshold cycle (C T ) values by the GAPDH C T values.
Methylation analysis
To analyse GPR54 promoter methylation, genomic DNA was extracted from cell lines using the QIAamp® DNA Mini Kit (QIAGEN) followed by treatment with sodium bisulfite using the EpiTect® BiSulfite kit (QIAGEN). Methylation-specific PCR (MS-PCR) was performed as previously reported (14) . For positive and negative controls, EpiTect® PCR Control DNA (QIAGEN) was used.
Epigenetic reactivation of GPR54 was examined by treating cells with 5µM 5-aza-DC (Sigma-Aldrich, measured using a WST-1 assay kit (a modified MTT assay using a water-soluble tetrazolium salts, Premix WST-1, Takara, Otsu, Japan) as described previously (17) and was compared between groups.
The experiment was carried out in sextuplicate.
Motility tracking assay
Ishikawa or HEC1A cells were placed into 6cm dish and incubated until they were 100% confluent. Experimental 'wounds' were introduced by dragging a 1 ml plastic pipette tip across the cell monolayer. After wounding, the cultured cells were rinsed with PBS and media was added with or without 10μM metastin-10. The cells were then incubated for 24h to track cell motility. A total of four wounds were sampled for each specimen. Migration rate was evaluated by measuring the gap between the cells most closely spaced on each leading edge at 0h and 24h post-wounding, expressed as the percentage of the distance filled. The motility of Ishikawa cells treated with or without metastin-10 was also tracked under a microscope equipped with a temperature-regulated stage and digital camera (IX71/AP71, Olympus, Tokyo, Japan). Cell images were captured every two minutes for 6h and movies were assembled using Metamorph (Molecular Devices, Sunnyvale, CA) as previously described (7). 
Invasion assay
Invasive potential into a reconstituted basement membrane was assayed on 24-well companion plates (Becton Dickinson Labware, Franklin Lakes, NJ) with an 8-μm pore polycarbonate filter coated with Matrigel ® (Becton Dickinson Labware) as described previously (17) . The lower chamber contained 0.8ml medium with 10% FBS as a chemoattractant. In the upper compartment, 1-2×10 6 cells in 0.2ml medium were seeded and incubated with or without metastin-10 peptide at 37℃ for 24h to allow for migration to the lower chamber. Student's t-tests were used to analyze the differences in invasion rates between groups. FTM080 (16), a peptide smaller than metastin-10, was also assessed in the same manner.
Microarray analysis
Gene expression microarray data (Affymetrix U133 Plus 2.0) for Ishikawa cells treated with or without 10μM metastin-10 and/or siRNAs were generated in triplicate and RMA-normalized as described previously (18, 19) . SAM was employed to detect the genes specifically expressed in metastin-10 treated cells with a false discovery rate (FDR) of less than 0.1 as described previously (18, 19). A metastasis gene signature was developed from two independent published microarray datasets, GSE11683 and GSE14405 (20), after removing batch effects using ComBat as previously described (21) .
Expression microarray data of endometrial cancers (GSE2109) (20) was also obtained from the website as above.
Orthotopic mouse model of endometrial cancer
Five to six-week CD1 Foxn1nu female mice were obtained from Oriental BioService, Inc.
(Kyoto, Japan). Animal care and experimental procedures were performed in accordance with the guidelines of the Institute of Laboratory Animals Graduate School of Medicine, Kyoto University. Subcutaneous xenografts were established by inoculating 1×10 7 Ishikawa cells into the flanks. Four weeks after inoculation, subcutaneous tumors were removed and cut into ~2mm 3 blocks for orthotopic implantation. One tumor block was implanted onto the uterine posterior wall in each of 21 mice, and these mice were divided into two groups. Each group was treated for 15 days with intraperitoneal administration of 50nmol metastin-10 or control, respectively, beginning four days after implantation.
Six weeks later, paraaortic lymph node metastasis was examined as previously described (22) 
Statistical analysis
Comparison of the groups was performed using Mann-Whitney U tests, while categorical variables were compared using χ2 tests. Overall survival was analyzed using the Kaplan-Meier method.
Statistical analyses were performed using GraphPad Prism 4 software. Probability values below 0.05 were considered significant. 
Results
GPR54 expression in endometrial cancers and its significance for prognosis
The expression of metastin and GPR54 in 92 endometrial cancer patients (mean age, 57.3 years)
was assessed by immunohistochemistry. Grade 1 endometrioid adenocarcinoma was observed in 36 patients, grade 2 in 12 patients, grade 3 in 31 patients, and serous adenocarcinoma in 13 patients. 
Effects of exogenous metastin on the phenotype of endometrial cancer
To examine the effect of exogenous metastin-10 on the phenotype of endometrial cancers with or without GPR54 expression, changes in proliferation, migration, and invasion were examined, effects that had previously been reported in several cancers (5, 23, 24) . GPR54 expression in eight endometrial Figure 3B ). We further confirmed this invasion-inhibitory effect of metastin-10 using GPR54+ KLE cells (p=0.0187), which was not evident in GPR54-HEC1A cells (p=0.8995). FTM080, a GPR54 agonistic smaller peptide, also showed similar effects on Ishikawa and KLE cells (p=0.0141 and 0.0009, respectively, Figure 3B ).
To determine whether metastin has an invasion-inhibitory role through interaction with its receptor GPR54, we examined the functional consequence of GPR54 knockdown using RNAi. We introduced four different GPR54 siRNAs into Ishikawa cells, each of which targeted independent sequences within GPR54 mRNA, and examined the efficiency of GPR54 knockdown using quantitative RT-PCR. Among these siRNAs, the knockdown efficiency of siRNA4 was most effective (48.29+/-2.98%) (supplementary figure 2), and thus was selected for further analysis. There was no significant difference in matrigel-invasion following GPR54 suppression (p=0.3516, Figure 3C ).
Metastin-10 significantly inhibited invasion of cells that received the negative control siRNA (p<0.0001), but not that of GPR54 suppressed cells (p=0.4169).
Methylation-dependent regulation of GPR54 expression and its targeting
GPR54 is reported to contain many CpG dinucleotides in the promoter region that are targeted by DNA methylation (14) . To assess potential epigenetic regulation of GPR54 expression in endometrial cancer cells, expression and methylation status was examined in 8 endometrial cancer cell lines using quantitative PCR and MS-PCR ( Figure 4A ). GPR54 expression was low and methylation was absent in non-malignant hEM cells. Methylation was present in seven cell lines and five of these showed evidence of complete methylation. Intriguingly, the expression of GPR54 was suppressed in these five cell lines relative to the other three cell lines (p=0.036). Promoter methylation was also observed in six of ten clinical samples (supplementary figure 3) . Moreover, GPR54 expression in all five GPR54-cell lines with methylation was restored following treatment with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine (5-aza-DC) (p=0.048, Figure 4B 
re-sensitizing GPR54-endometrial cancers cells to metastin treatment using 5-aza-DC. Following 5-aza-DC pretreatment, the ability to invade matrigel in both GPR54-cell lines, HEC1A and AN3CA, was significantly inhibited after metastin-10 addition (Figure 4D , p=0.0034 and 0.0022, respectively), while this was not observed in cells pretreated with 5-aza-DC but without the addition of metastin-10 (p=0.1797 and 0.6991, respectively).
Usefulness of metastin as a treatment to suppress GPR54+ endometrial cancer metastasis
Although there are several reports showing metastin inhibits migration and invasion of cancer cells in vitro, it is not clear whether cancer cells treated with metastin in vivo will become less metastatic.
Genome-wide analysis of gene expression changes following metastin-10 treatment, using the web software named of GATHER (25) , revealed that 318 probes (285 genes) were downregulated in Ishikawa cells, and "cell motility" (GO:0006928) as well as "regulation of cellular physiological process" (GO:0051244) were Gene Ontology (GO) terms enriched among these genes. Next, a metastasis gene signature was developed using the Bayesian binary method (26) from available microarray datasets that 
signature to accurately assign the status of metastatic and non-metastatic cells was 100%. The propriety of this signature was externally validated in GSE2109, in which the metastasis signature probability was significantly higher in grade 3 endometrial cancers at stage III-IV than those at stage I-II (p=0.028, supplementary figure 4). The metastasis signature consisted of 172 upregulated and 28 downregulated probes in highly metastatic subclones, and protein transport GO terms such as "intracellular protein transport" (GO:0006886) and "establishment of protein localization" (GO:0045184) as well as "cellular physiological process" (GO:0050875) were enriched among the upregulated probes. This metastasis signature was applied to the microarray data from Ishikawa cells with/without metastin-10 treatment to assign a metastatic probability to each group (microarray data are available at GEO repository with the accession No. GSE25458). The metastasis signature probability was significantly suppressed by metastin-10 treatment (p=0.0395, Figure 5A ), while the probability was not changed following GPR54 knockdown (p=0.5250). Intriguingly, metastatic suppression with metastin-10 treatment was not observed in GPR54 knockdown cells (p=0.8757).
Using a lymph node metastasis model (22) , the suppressive effect of metastin-10 on metastasis was assessed in vivo. Six weeks after inoculation of a 2mm 3 Figure 5C ). Tumor cell infiltration that resembled the primary site was observed in swollen paraaortic lymph nodes beneath the left renal vein, and they were positive for both human cytokeratin and the estrogen receptor ( Figure 5C ). Although there was no difference in the diameter of uterine tumors treated with/without metastin-10, paraaortic nodes in the group treated with metastin-10 were smaller (2.45+/-0.55mm) than those without metastin-10 (4.1+/-1.25mm, p=0.1686). Since all the lymph nodes positive for metastasis in microscopic examination was also positive for the expression of human β2-microglobulin in RT-PCR, the presence of tumor cells in lymph nodes was confirmed by the expression of human β2-microglobulin, which revealed that paraaortic metastasis was less frequent in the group treated with metastin-10 (p=0.029, Figure 5D ).
Together, the results obtained from the microarray analysis and the orthotopic endometrial cancer metastasis model demonstrates the ability of metastin-10 to suppress metastasis of GPR54+ endometrial cancers in vivo. Metastasis is a critical factor that determines the prognosis of patients with endometrial cancer.
To confirm the genetic propensity toward a metastatic phenotype in high grade histology tumors, we analyzed microarray data of 146 endometrial cancers for expression of metastasis suppressor genes. prognosis of patients with endometrial carcinomas negative for GPR54 expression was significantly poorer than those positive for GPR54. These results strongly suggest that decreased expression of GPR54 is a poor prognostic factor and is relevant to both invasive and metastatic capacity of endometrial cancers. On the other hand, metastin is ubiquitously expressed both in cancer and stromal cells, irrespective of histological grade, and expression is not relevant to patient prognosis. The weak expression of metastin in stromal cells might prevent invasion of cancer cells, which was not clarified in this study.
Migration and invasion of cancer cells into the stroma or vascular space is regarded as the initial step of distant metastasis. We next examined if the metastin-GPR54 axis is relevant to the migration and invasion of endometrial cancer cells in vitro. Previous reports showed that metastin prevented migration or invasion in several cancers (23, (28) (29) (30) and HUVEC (31). In this study, we used metastin-10, a short peptide of 10 amino acids which is proteolytically processed from metastin.
Metastin-10 is ten times as active as metastin and regarded as a candidate for clinical use (16) . Migration of the GPR54+ Ishikawa endometrial cancer cell line was significantly inhibited by metastin-10 in the wound healing assay, while proliferation was not affected. These findings were confirmed using these cells was also inhibited by metastin-10 as evaluated using the Boyden chamber assay. In contrast, these inhibitory effects of metastin-10 on migration and invasion were not observed in GPR54-HEC1A cells, and siRNA-mediated knockdown of GPR54 resulted in lack of response of Ishikawa cells to metastin-10 treatment. These findings suggest that the effect of metastin is exclusively dependent on its receptor, GPR54.
To evaluate if metastin treatment alters gene expression patterns, we conducted gene expression microarray analysis of Ishikawa cells that were treated with or without metastin-10. By comparing gene expression of highly metastatic cancer subclones with their parental cells, a metastatic probability score was generated using the Bayesian binary method (26) . The calculated metastatic probability score was significantly decreased after metastin-10 treatment, suggesting that metastin converted Ishikawa cells to a less metastatic phenotype. This was not observed when GPR54 was suppressed by siRNA treatment, again indicating that the effect of metastin is receptor-dependent. These results are in agreement with the previously reported anti-metastatic effects of metastin on intracellular signaling pathways (7, 32). 
by promoter hypermethylation is frequent for a number of genes such as PTEN, p16, and RASSF1A (33, 34). Chemical genomic screening of gastric cancer cell lines showed several metastasis suppressor genes including GPR54, BMP7, IGFBP3, and MTSS1 are silenced by DNA methylation (14) . In this study, promoter methylation was present in seven endometrial cell lines and five of these showed complete methylation, while methylation was not observed in hEM cells derived from normal endometrium.
Notably, the expression of GPR54 was suppressed in the five completely methylated cell lines relative to the other three cell lines (p<0.05). These findings indicate that expression of GPR54 is epigenetically regulated in endometrial cancers. Considering that GPR54-endometrial cancers have a poor prognosis and a highly metastatic phenotype, combined with the fact that metastin-10 does not inhibit migration and invasion of endometrial cancer cells lacking GPR54, restoration of GPR54 is crucial to bring about the efficacy of metastin treatment on GPR54-endometrial cancers in preventing metastasis. In this regard, we tried to restore GPR54 expression in five GPR54-endometrial cancer cell lines by alleviating GPR54 promoter hypermethylation using 5-aza-DC. Following 5-aza-DC pretreatment, matrigel invasion of both GPR54-cell lines, HEC1A and AN3CA, was significantly inhibited with metastin-10.
Thus, epigenetically-mediated restoration of GPR54 using hypomethylating agents might provide a means to resensitize cells to the antimetastatic effects of metastin-10 in GPR54-endometrial cancers.
Since 5-aza-DC is already used in clinical settings (35) Finally, the in vivo effect of metastin-10 was confirmed using a recently established orthotopic model in which metastatic ability of human endometrial cancer cells can be evaluated by assessing paraaortic lymph node metastasis from uterine transplants in nude mice (22) . The frequency of lymph node metastases of GPR54+ Ishikawa cells was significantly diminished in metastin-10-treated mice.
The fact that tumor size at the primary site was not significantly different between the metastin-treated and non-treated groups indicates that metastin predominantly affects metastatic potential rather than tumor growth. This is the first animal model that demonstrates the efficacy of peptide administration on the prevention of nodal metastasis from endometrial cancer with deep myometrial invasion. In clinical settings, the rate of nodal metastases approaches 26% in cases with deep myometrial invasion, and the 5-year survival rate of such cases is 30% less than those without nodal metastasis (2) . In this regard, metastin-10 treatment may be effective in preventing nodal metastasis in cases with deep myometrial invasion and provide a safer alternative to lymphadenectomy. 
